← Back to Search

Cancer Imaging Agent

FAPI-74 PET/MRI for Dermatomyositis (FAPI-74 Trial)

Phase 2

Waitlist Available

Research Sponsored by Farshad Moradi

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Patients with suspected dermatomyositis

Patient must be over 18 years old

Must not have

Contraindication to MRI or inability to lie flat for 30 min

Women who are pregnant or potentially pregnant per the Department of Radiology Policy on Imaging in Potentially Pregnant and Pregnant Women

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 1 hour

Awards & highlights

No Placebo-Only Group

Summary

This trial aims to use a type of imaging called PET with a specific isotope to study patients with Refractory Dermatomyositis at one medical center.

Who is the study for?

This trial is for individuals with refractory dermatomyositis, a condition where standard treatments haven't worked. Participants must meet certain health criteria to be included, but specific inclusion and exclusion details are not provided in the given information.

What is being tested?

[18F]-FAPI-74 PET/MRI imaging is being tested in this study. It's a single-center, single-arm trial which means all participants will receive the same intervention without comparison to another group or treatment.

What are the potential side effects?

Potential side effects of [18F]-FAPI-74 PET/MRI imaging are not detailed in the provided information. Generally, PET scans have minimal side effects related to exposure to radioactive tracers.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I might have dermatomyositis.

Select...

I am over 18 years old.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:

Select...

I cannot have an MRI or lie flat for 30 minutes.

Select...

I am not pregnant nor planning to become pregnant soon.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 1 hour

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 1 hour

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 1 hour for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Rate of [18F]-FAPI-74 uptake.

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups

Experimental Treatment

Group I: [18F]-FAPI-74 PET/ MRIExperimental Treatment1 Intervention

Participant receive \[18F\]-FAPI-74 injection and approximately 45-60 minutes later receive a MRI scan from vertex to legs, followed by a static PET emission scan over the same area.

0 / 4Eligibility criteria met